Submit Manuscript  

Article Details


Successful Treatment for Severe Thyroid-associated Ophthalmopathy with Tocilizumab

[ Vol. 18 , Issue. 6 ]

Author(s):

Carlos A. Canas*, Fabio Bonilla-Abadia, Katherine Vallejo, Hector M. Rengifo, Marco A. Gallon and Gabriel J. Tobon   Pages 665 - 667 ( 3 )

Abstract:


Background and Objective: Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of Graves disease, occasionally severe and refractory to treatment, mainly in long-term disease. In these cases, one of the most important infiltrating cytokines in the orbital tissue is interleukin-6 (IL-6).

Methods: This is a case report, the methodology consisted of the application of tocilizumab in a patient with graves disease and the patient's follow-up.

Results: We present the case of a 54-year-old male with TAO who responded adequately to treatment with tocilizumab, an antibody directed against the IL-6 receptor.

Conclusion: Tocilizumab could be an optional treatment in patients with TAO.

Keywords:

Thyroid-associated ophthalmopathy, Graves` associated ophthalmopathy, tocilizumab, IL-6, extrathyroidal manifestation, infiltrating cytokines.

Affiliation:

GIRAT: Grupo de investigacion en Reumatologia, Autoinmunidad y Medicina Traslacional, Fundacion Valle del Lili and Universidad Icesi, Cali, GIRAT: Grupo de investigacion en Reumatologia, Autoinmunidad y Medicina Traslacional, Fundacion Valle del Lili and Universidad Icesi, Cali, GIRAT: Grupo de investigacion en Reumatologia, Autoinmunidad y Medicina Traslacional, Fundacion Valle del Lili and Universidad Icesi, Cali, Department of Endocrinology, Clinica Sebastian de Belalcazar, Colsanitas. Cali, Deparment of Ophthalmology, Oculoplastic and Orbital Surgery, Clinica de Oftalmologia de Cali, Cali, GIRAT: Grupo de investigacion en Reumatologia, Autoinmunidad y Medicina Traslacional, Fundacion Valle del Lili and Universidad Icesi, Cali

Graphical Abstract:



Read Full-Text article